{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:37:06Z","timestamp":1761061026173},"reference-count":21,"publisher":"Institute of Physiology of the Czech Academy of Sciences","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiol Res"],"published-print":{"date-parts":[[2015,12,28]]},"abstract":"<jats:p>Phenobarbital is an anticonvulsive drug widely used in newborns with hypoxic-ischemic encephalopathy. The objective of our study was to describe possible effect of frequently co-administered medications (dopamine, dobutamine, norepinephrine, furosemide, phenytoin, and analgesics) on the phenobarbital pharmacokinetics in full term newborns with hypoxic-ischemic encephalopathy. Phenobarbital pharmacokinetic parameters (standardized intravenous loading dose was 10-20 mg\/kg, maintenance dose 2-6 mg\/kg\/day) were computed using non-compartmental analysis. Co-medication was evaluated throughout the whole treatment period up to 5 days. Volume of distribution, clearance, and half-life median values (95 % CI) for phenobarbital in the whole study population (n=37) were 0.48 (0.41-0.56) l\/kg, 0.0034 (0.0028-0.0040) l\/h\/kg, and 93.7 (88.1-99.2) h, respectively. Phenobarbital pharmacokinetic parameters were not significantly affected by vasoactive drugs (dopamine, dobutamine, and norepinephrine), furosemide, phenytoin, or analgesics. Furthermore, no dose-dependent alteration of phenobarbital pharmacokinetic parameters was noted for vasoactive medication at doses equivalent to cumulative vasoactive-inotropic score (area under the curve in a plot of vasoactive-inotropic score against time) 143.2-8473.6, furosemide at cumulative doses of 0.2-42.9 mg\/kg, or phenytoin at cumulative doses of 10.3-46.2 mg\/kg. Phenobarbital pharmacokinetics was not affected by investigated co-administered drugs used in newborns with hypoxic-ischemic encephalopathy in real clinical settings.<\/jats:p>","DOI":"10.33549\/physiolres.933213","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T10:14:38Z","timestamp":1587636878000},"page":"S513-S519","source":"Crossref","is-referenced-by-count":11,"title":["Effect of Co-Medication on the Pharmacokinetic Parameters of Phenobarbital in Asphyxiated Newborns"],"prefix":"10.33549","author":[{"given":"M.","family":"\u0160\u00cdMA","sequence":"first","affiliation":[{"name":"Department of Pharmacology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"POKORN\u00c1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"HRONOV\u00c1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"SLANA\u0158","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"19169","published-online":{"date-parts":[[2015,12,12]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"ALCORN J, MCNAMARA PJ: Pharmacokinetics in the newborn. Adv Drug Deliv Rev 55: 667-686, 2003.","DOI":"10.1016\/S0169-409X(03)00030-9"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"BONETT DG, PRICE RM: Statistical inference for a linear function of medians: confidence intervals, hypothesis testing, and sample size requirements. Psychol Methods 7: 370-383, 2002.","DOI":"10.1037\/1082-989x.7.3.370"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"BRODIE MJ, MINTZER S, PACK AM, GIDAL BE, VECHT CJ, SCHMIDT D: Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia 54: 11-27, 2013.","DOI":"10.1111\/j.1528-1167.2012.03671.x"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"ENCINAS MP, SANTOS BUELGA D, ALONSO GONZ\u00c1LEZ AC, GARC\u00cdA S\u00c1NCHEZ MJ, DOM\u00cdNGUEZ-GIL HURL\u00c9 A: Influence of length of treatment on the interaction between phenobarbital and phenytoin. J Clin Pharm Ther 17: 49-50, 1992.","DOI":"10.1111\/j.1365-2710.1992.tb01264.x"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"FILIPPI L, LA MARCA G, CAVALLARO G, FIORINI P, FAVELLI F, MALVAGIA S, DONZELLI G, GUERRINI R: Phenobarbital for neonatal seizures in hypoxic ischemic encephalopathy: a pharmacokinetic study during whole body hypothermia. Epilepsia 52: 794-801, 2011.","DOI":"10.1111\/j.1528-1167.2011.02978.x"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"FISCHER JH, LOCKMAN LA, ZASKE D, KRIEL R: Phenobarbital maintenance dose requirements in treating neonatal seizures. Neurology 31: 1042-1044, 1981.","DOI":"10.1212\/wnl.31.8.1042"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"GAL P, BOER HR, TOBACK J, ERKAN NV: Phenobarbital dosing in neonates and asphyxia. Neurology 32: 788-789, 1982.","DOI":"10.1212\/wnl.32.7.788"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"GORSKI JC, HALL SD, JONES DR, VANDENBRANDEN M, WRIGHTON SA: Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47: 1643-1653, 1994.","DOI":"10.1016\/0006-2952(94)90543-6"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"HALL RT, HALL FK, DAILY DK: High-dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three-year follow-up. J Pediatr 132: 345-348, 1998.","DOI":"10.1016\/s0022-3476(98)70458-5"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"KUMAR M, SHARMA R, SETHI SK, BAZAZ S, SHARMA P, BHAN A, KHER V: Vasoactive Inotrope Score as a tool for clinical care in children post cardiac surgery. Indian J Crit Care Med 18: 653-658, 2014.","DOI":"10.4103\/0972-5229.142174"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"KWAN P, BRODIE MJ: Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia 45: 1141-1149, 2004.","DOI":"10.1111\/j.0013-9580.2004.12704.x"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"O'DONOVAN BH, BELL EF: Effects of furosemide on body water compartments in infants with bronchopulmonary dysplasia. Pediatr Res 26: 121-124, 1989.","DOI":"10.1203\/00006450-198908000-00010"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"PATSALOS PN, BERRY DJ, BOURGEOIS BF, CLOYD JC, GLAUSER TA, JOHANNESSEN SI, LEPPIK IE, TOMSON T, PERUCCA E: Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 49: 1239-1276, 2008.","DOI":"10.1111\/j.1528-1167.2008.01561.x"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"RICHER M, ROBERT S, LEBEL M: Renal hemodynamics during norepinephrine and low-dose dopamine infusions in man. Crit Care Med 24: 1150-1156, 1996.","DOI":"10.1097\/00003246-199607000-00014"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"SCHETZ M: Vasopressors and the kidney. Blood Purif 20: 243-251, 2002.","DOI":"10.1159\/000047016"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"SHELLHAAS RA, NG CM, DILLON CH, BARKS JD, BHATT-MEHTA V: Population pharmacokinetics of phenobarbital in infants with neonatal encephalopathy treated with therapeutic hypothermia. Pediatr Crit Care Med 14: 194-202, 2013.","DOI":"10.1097\/pcc.0b013e31825bbbc2"},{"key":"ref16","unstructured":"SUBRAHMANYAM V, RENWICK AB, WALTERS DG, YOUNG PJ, PRICE RJ, TONELLI AP, LAKE BG: Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab Dispos 29: 1146-1155, 2001."},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"TATEISHI T, KRIVORUK Y, UENG YF, WOOD AJ, GUENGERICH FP, WOOD M: Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth Analg 82: 167-172, 1996.","DOI":"10.1213\/00000539-199601000-00031"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"TOUW DJ, GRAAFLAND O, CRANENDONK A, VERMEULEN RJ, VAN WEISSENBRUCH MM: Clinical pharmacokinetics of phenobarbital in neonates. Eur J Pharm Sci 12: 111-116, 2000.","DOI":"10.1016\/s0928-0987(00)00145-7"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"VAN DEN BROEK MP, GROENENDAAL F, TOET MC, VAN STRAATEN HL, VAN HASSELT JG, HUITEMA AD, DE VRIES LS, EGBERTS AC, RADEMAKER CM: Pharmacokinetics and clinical efficacy of phenobarbital in asphyxiated newborns treated with hypothermia: a thermopharmacological approach. Clin Pharmacokinet 51: 671-679, 2012.","DOI":"10.1007\/s40262-012-0004-y"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"ZANELLI S, BUCK M, FAIRCHILD K: Physiologic and pharmacologic considerations for hypothermia therapy in neonates. J Perinatol 31: 377-386, 2011.","DOI":"10.1038\/jp.2010.146"}],"container-title":["Physiological Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T10:14:42Z","timestamp":1587636882000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomed.cas.cz\/physiolres\/pdf\/64%20Suppl%204\/64_S513.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,12]]},"references-count":21,"URL":"https:\/\/doi.org\/10.33549\/physiolres.933213","relation":{},"ISSN":["1802-9973","0862-8408"],"issn-type":[{"value":"1802-9973","type":"electronic"},{"value":"0862-8408","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12,12]]}}}